Print

Results From Gentium S.p.A.'s Treatment IND for Defibrotide Presented at the American Society of Hematology Annual Meeting  
12/13/2012 9:50:42 AM

VILLA GUARDIA (COMO), Italy, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that additional data from ongoing trials of Defibrotide were presented this week at the 54th Annual Meeting and Exposition of the American Society of Hematology (ASH) held at the Georgia World Congress Center in Atlanta, Georgia.
//-->